OR WAIT null SECS
April 10, 2018
The new 300,000-square-foot facility is considered the largest dedicated cell and gene therapy manufacturing facility with fully integrated services.
April 09, 2018
Under this global collaboration, the companies will develop encapsulated cell therapies for treating Type 1 diabetes.
March 26, 2018
Hitachi will manufacture regenerative medicines developed by Daiichi Sankyo and SanBio Group.
The agreement gives IncoCell Tianjin, a wholly-owned subsidiary of China-based Boyalife Group, access to Cesca’s celluar processing contract development and manufacturing services.
March 23, 2018
The collaboration between the two companies aims to finish all necessary work needed to file for a first-in-human study by early 2019.
February 21, 2018
The companies have partnered to develop and commercialize vectorized antibodies against tau for Alzheimer's and other neurodegenerative diseases.
February 12, 2018
The companies have been awarded a collaborative grant of £1.9 million (US$2.6 million) from Innovate UK.
February 02, 2018
Greater clarity and harmonization in ATMP regulations are needed to promote the development and commercialization of these therapies.
January 19, 2018
GE Healthcare will equip Cellular Biomedicine Group's cell therapy manufacturing facility in Shanghai, China, with its FlexFactory single-use platform, designed to speed up cell therapy manufacturing timelines.
January 18, 2018
The company is developing a pipeline of combination therapies using its patented polymer-based matrix delivery system, known as TAOS (targeted orchestrated signalling matrix).